PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium

The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC). Notwithstanding, little information exists regarding the expression of the alternative PD-1 ligand, PD-L2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowell, Alexander C., Munford, Haydn, Goel, Anshita, Gordon, Naheema S., James, Nicholas D., Cheng, K. K., Zeegers, Maurice P., Ward, Douglas G., Bryan, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951139/
https://www.ncbi.nlm.nih.gov/pubmed/33718196
http://dx.doi.org/10.3389/fonc.2021.626748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951139/
https://www.ncbi.nlm.nih.gov/pubmed/33718196
http://dx.doi.org/10.3389/fonc.2021.626748

Ejemplares similares